Nintedanib
VEGFR, PDGFR and FGFR kinase inhibitor / Nintedanib is a potent inhibitor of VEGFR, PDGFR, FGFR (IC50 = 13-34 nM for VEGFR, 59-65 nM for PDGFR and 37-108 nM for FGFR subtypes).1 Also inhibits Flt-3, Lck, Lyn and Src (IC50 = 16-156 nM). Inhibits VEGF-stimulated proliferation of HUVECs.1 Inhibits tumor growth in a mouse tumor xenograft model.1 A novel therapeutic agent for treatment of idiopathic pulmonary fibrosis.2,3 Alleviates chronic pancreatitis by inhibiting the activation of pancreatic stellate cells.4
Biochemicals & reagents
656247-17-5
BIBF-1120
1 Hilberg et al. (2008), BIBF-1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy; Cancer Res. 68 4774 2 Dimitroulis et al. (2014), Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis; Respir. Care 59 1450 3 Guo et al. (2023), Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies; Front. Pharmacol. 14 1205948 4 Han et al. (2023), Nintedanib Alleviates Chronic Pancreatitis by Inhibiting the Activation of Pancreatic Stellate Cells via the JAK/STAT3 and ERK1/2 Pathways; Dig. Dis. Sci. 68 3644
-20°C
TARGET: Kinase -- RESEARCH AREA: Angiogenesis -- DISEASE AREA: Cancer